AI assistant
BIO-TECHNE Corp — Director's Dealing 2017
Aug 15, 2017
30718_dirs_2017-08-15_6ac4b78d-8dfb-4896-acdb-64b591586c1a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2017-08-12
Reporting Person: Kummeth Charles R. (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-12 | Common Stock | M | 9248 | — | Acquired | 70278 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-12 | Stock Option (Right to Buy) | $94.35 | A | 66849 | Acquired | 2021-08-12 | Common Stock (66849) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $67.46 | 2020-04-01 | Common Stock (65000) | 65000 | Direct |
| Stock Option (Right to Buy) | $67.46 | 2020-04-01 | Common Stock (50000) | 50000 | Direct |
| Stock Option (Right to Buy) | $86.25 | 2021-04-01 | Common Stock (46316) | 46316 | Direct |
| Stock Option (Right to Buy) | $108.49 | 2022-08-07 | Common Stock (79517) | 79517 | Direct |
| Stock Option (Right to Buy) | $108.49 | 2022-08-07 | Common Stock (119275) | 119275 | Direct |
| Restricted Stock Unit | $ | Common Stock (17283) | 17283 | Direct | |
| Stock Option (Right to Buy) | $106.59 | 2023-08-18 | Common Stock (102779) | 102779 | Direct |
| Stock Option (Right to Buy) | $106.59 | 2023-08-18 | Common Stock (154169) | 154169 | Direct |
| Restricted Stock Unit | $ | Common Stock (24979) | 24979 | Direct |
Footnotes
F1: On August 12, 2014, the reporting person was granted 11,129 restricted stock units (previously reported). The restricted stock units would vest in full or in part on August 12, 2017 if certain performance goals were achieved during each of the 2015, 2016 and 2017 fiscal years. The performance criteria was determined, resulting in the restricted stock unit vesting as to 9,248 shares.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Includes (i) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; (ii) 3,841 shares for which the risks of forfeiture will lapse on August 7, 2018; and (iii) 16,653 shares for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2017, August 18, 2018 and August 18, 2019.
F4: Fully exercisable.
F5: The option will vest pursuant to the following schedule: 5,790 shares on October 1, 2014, 965 shares on the first day of the month for the period beginning November 1, 2014 and ending March 1, 2018, and 961 shares on April 1, 2018.
F6: Fully exercisable pursuant to achievement of performance goals.
F7: On August 12, 2014, the reporting person was granted an option to purchase 80,460 shares of common stock (previously reported). The option would vest in full or in part on August 12, 2017 if certain performance goals were achieved during each of the 2015, 2016 and 2017 fiscal years. The performance criteria was determined, resulting in the option vesting as to 66,849 shares.
F8: 19,879 shares vest on each of August 7, 2016, August 7, 2017 and August 7, 2018 and 19,880 shares vest on August 7, 2019.
F9: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F11: Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.
F12: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).